Novartis wins approval for diabetes treatment

New drug approved for Novartis Keystone

Novartis has been given the go-ahead to market a new type of drug, called Starlix, for the treatment of type two diabetes.

This content was published on October 5, 2000

The Basel-based life sciences group said the approval was based on clinical data involving more than 4,000 patients, and is the first approval for Starlix in Europe.

It is estimated that approximately a quarter of a million people suffer from type two diabetes in Switzerland.

Starlix is one of the potential next generation of blockbuster drugs for Novartis. The company has teamed up with Germany's Merck group to co-promote and co-market the product in Europe and in certain African, Southeast Asian and Latin American countries.

Starlix is licensed by Novartis from Ajinomoto of Japan.

swissinfo with agencies

In compliance with the JTI standards

In compliance with the JTI standards

More: SWI certified by the Journalism Trust Initiative

Contributions under this article have been turned off. You can find an overview of ongoing debates with our journalists here. Please join us!

If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at

Sort by

Change your password

Do you really want to delete your profile?

Your subscription could not be saved. Please try again.
Almost finished... We need to confirm your email address. To complete the subscription process, please click the link in the email we just sent you.

Weekly top stories

Keep up to date with the best stories from SWI on a range of topics, straight into your mailbox.


The SBC Privacy Policy provides additional information on how your data is processed.